December 9, 2013

By riddock57

Dec 8, 2013 6:05:21 PM PST

Idenix

Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX)

Hepatitis means inflammation of the liver. There are many causes of hepatitis. For example, drinking too much alcohol, various drugs and chemicals, and also several different viruses can cause hepatitis.

Hepatitis C, a virus which is carried in the bloodstream to the liver, is one of several hepatitis viruses and is generally considered to be among the most serious of these viruses. Hepatitis C is passed through contact with contaminated blood — most commonly through needles shared during illegal-drug use.

Chronic hepatitis C is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States

On Friday, Gilead Sciences, Inc. reported that the FDA has approvedSovaldi(TM) (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C(CHC) infection as a component of a combination antiviral treatment regimen.

The Wholesaler Acquisition Cost (WAC) of a 28-tablet bottle of Sovaldi in the United States is $28,000

IDIX recently reported that it has filed two lawsuits against Gilead: a patent infringement lawsuit in the U.S. District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the U.S. District Court in Wilmington, Delaware.

The Massachusetts infringement lawsuit alleges that Gilead infringes two U.S. patents co-owned byIDIX (6,914,054 and 7,608,597) that cover methods of treating the hepatitis C virus using 2'-methyl nucleosides. In this lawsuit, IDIX is seeking a declaration that Gilead's imminent distribution, importation, use, sale or offer to sell drugs-containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents.

The Delaware infringement and interference lawsuit alleges that Gilead infringes a separate U.S. patent co-owned by IDIX (7,608,600) that covers methods of treating the hepatitis C virus using 2'-methyl-2'-fluoro nucleosides. IDIX is seeking a declaration that Gilead's imminent distribution, importation, use, sale or offer to sell drugs-containing sofosbuvir infringes the IDIX '600 patent. Additionally, the Delaware lawsuit asserts a claim for interfering patents between the IDIX '600 patent and a U.S. patent (8,415,322) owned by a Gilead subsidiary, Gilead Pharmasset LLC. IDIX is seeking to have the Gilead '322 patent declared invalid.

Source

0 comments :

Post a Comment